Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4685 in Relapsed or Refractory T Cell Lymphoma and CLL/SLL
NCT06547528Phase 1Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Oct 2023
- Primary completion
- Jan 2029
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ONO-4685 in T-cell lymphoma, chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by Ono Pharmaceutical. Primary endpoints: Dose-limiting toxicities at 3 weeks, Incidence and severity of Adverse Events and Serious Adverse Events at 1 year and 3 more. Started Oct 2023; status: active, not recruiting.
02
Drugs
ONO-4685
03
Conditions
T-cell lymphomachronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT06547528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06547528.